9/806,836 EAS1

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1679	quinazolin or qinazolinyl	US-PGPUB; USPAT	OR	OFF	2005/02/04 14:34
L2	34938	angiogenesis or atherosclerosis	US-PGPUB; USPAT	OR	OFF	2005/02/04 14:34
L3	502	L1 and L2	US-PGPUB; USPAT	OR	OFF	2005/02/04 15:10
L4	160	L3 and (triazin or triazinyl)	US-PGPUB; USPAT	OR	OFF	2005/02/04 14:35
L5	275	L3 and (oxy or thio)	US-PGPUB; USPAT	OR	OFF	2005/02/04 14:43
L6	333	L3 not (phenylamino or anilino)	US-PGPUB; USPAT	OR	OFF	2005/02/04 15:11
L7	172	L6 and (oxy or thio)	US-PGPUB; USPAT	OR	OFF	2005/02/04 15:11

09/ 806,836

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	4	OCT 28	KOREAPAT now available on STN
NEWS	5	NOV 30	PHAR reloaded with additional data
NEWS	6	DEC 01	LISA now available on STN
NEWS	7	DEC 09	12 databases to be removed from STN on December 31, 2004
NEWS	8	DEC 15	MEDLINE update schedule for December 2004
NEWS	9	DEC 17	ELCOM reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	10	DEC 17	COMPUAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	11	DEC 17	SOLIDSTATE reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	12	DEC 17	CERAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	13	DEC 17	THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB
NEWS	14	DEC 30	EPFULL: New patent full text database to be available on STN
NEWS	15	DEC 30	CAPLUS - PATENT COVERAGE EXPANDED
NEWS	16	JAN 03	No connect-hour charges in EPFULL during January and February 2005
NEWS	17	JAN 26	CA/CAPLUS - Expanded patent coverage to include the Russian Agency for Patents and Trademarks (ROSPATENT)

NEWS EXPRESS	JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:07:54 ON 04 FEB 2005

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:08:02 ON 04 FEB 2005

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 2 FEB 2005 HIGHEST RN 824932-81-2
DICTIONARY FILE UPDATES: 2 FEB 2005 HIGHEST RN 824932-81-2

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> s thiophenoxy
L1 91 THIOPHENOXY

=> d scan l1

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Sulfonium, diphenyl[4-(phenylthio)phenyl]-, salt with trifluoromethanesulfonic acid (1:1) (9CI)
MF C24 H19 S2 . C F3 O3 S

CM 1



CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Diazene, (1,1-dimethylethyl)[1-[[4-(1,1-dimethylethyl)phenyl]thio]-1-methylethyl]- (9CI)
MF C17 H28 N2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Phenylthio (6CI, 7CI, 8CI, 9CI)
MF C6 H5 S



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3-
'3-' IS NOT VALID HERE

To display more answers, enter the number of answers you would like to see. To end the display, enter "NONE", "N", "0", or "END".
HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Methanone, [4-[(4-chlorophenyl)thio]phenyl]phenyl- (9CI)
MF C19 H13 Cl O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Diazene, (1,1-dimethylethyl)[1-phenyl-1-(phenylthio)ethyl]- (9CI)
MF C18 H22 N2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Acetic acid, (phenylthio)-, methyl ester (6CI, 7CI, 8CI, 9CI)
MF C9 H10 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):90

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2-Propanamine, 2-methyl-1-[4-(methylthio)phenoxy]-, hydrochloride (9CI)
MF C11 H17 N O S . Cl H



L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Diazene, (1,1-dimethylethyl)[1-methyl-1-(phenylthio)ethyl]- (9CI)
MF C13 H20 N2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzene, 1-(methylthio)-4-phenoxy- (9CI)
MF C13 H12 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1H-Pyrrole-2,5-dione, 1-[[4-[4-(methylthio)phenoxy]phenyl]methyl]- (9CI)
MF C18 H15 N O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Pentanoic acid, 4-[(1,1-dimethylethyl)azo]-4-(phenylthio)-, butyl ester (9CI)

MF C19 H30 N2 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,1':2',1''-Terphenyl, 2-(phenylthio)- (9CI)
MF C24 H18 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Oxazole, 4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-5-[3-[2-(methylthio)phenoxy]propyl]- (9CI)
MF C23 H22 Cl N3 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Acetic acid, chloro-, 2-(phenylthio)ethyl ester (9CI)
MF C10 H11 Cl O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Ethanol, 2-[2-(methylthio)phenoxy]- (9CI)
MF C9 H12 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1-Piperidineethanol, α-[(benzo[b]thien-4-yloxy)methyl]-4-(6-fluoro-2-naphthalenyl)-, (αS)- (9CI)
MF C26 H26 F N O2 S

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Cyclopentanol, 2-[4-(phenylthio)phenoxy]- (9CI)
MF C17 H18 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,4-Benzenedicarbonitrile, 2-[(4-nitrophenyl)thio]- (9CI)
MF C14 H7 N3 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2-Thiophenebutanol, β-amino-β-methyl-5-[3-[4-(methylthio)phenoxy]-1-propynyl]-, dihydrogen phosphate (ester) (9CI)
MF C19 H24 N O5 P S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2-Propanol, 1-phenoxy-3-(phenylthio)- (9CI)
MF C15 H16 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Carbonochloridic acid, 4-[(1,1-dimethylethyl)azo]-4-[[4-(1,1-dimethylethyl)phenyl]thio]pentyl ester (9CI)

09/ 806,836

MF C20 H31 Cl N2 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Acetic acid, (phenylthio)- (6CI, 7CI, 8CI, 9CI)
MF C8 H8 O2 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Sulfonium, diphenyl[4-(phenylthio)phenyl]-, salt with 4-methylbenzenesulfonic acid (1:1) (9CI)
MF C24 H19 S2 . C7 H7 O3 S

CM 1



CM 2



L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Diazene, (1,1-dimethylethyl)[1,3-dimethyl-1-(phenylthio)butyl]- (9CI)
MF C16 H26 N2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzenamine, 3-(phenylthio)- (9CI)
MF C12 H11 N S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Ethanamine, 2-[4-[4-(methylthio)phenoxy]phenoxy]- (9CI)
MF C15 H17 N O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Magnesium, (benzenethiolato)bromo- (9CI)
MF C6 H5 Br Mg S



L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Sulfide, bis[m-[m-(phenylthio)phenoxy]phenyl] (8CI)
MF C36 H26 O2 S3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzene, 1,1'-[1,3-propanediylbis(thio)]bis[4-(1,1-dimethylethyl)-2-isocyano- (9CI)
MF C25 H30 N2 S2



L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Diazene, (1,1-dimethylethyl)[3-methoxy-1,3-dimethyl-1-(phenylthio)butyl]- (9CI)
MF C17 H28 N2 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Silane, (phenylthio)- (8CI, 9CI)
MF C6 H8 S Si



L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzoxazole, 2,2'-[2,5-bis(phenylthio)-1,4-phenylene]bis- (9CI)
MF C32 H20 N2 O2 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Diazene, (1,1-dimethylethyl)[1-[[4-(1,1-dimethylethyl)phenyl]thio]cyclohex yl]- (9CI)
MF C20 H32 N2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN p-Toluenesulfonamide, N-[5,8-diamino-7-chloro-6-(phenylthio)-1-anthraquinonyl]- (8CI)
MF C27 H20 Cl N3 O4 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN

IN Pyrazine, 2-[2-[2-(methylthio)phenoxy]ethoxy]-3-(1-piperazinyl)-, (2Z)-2-butenedioate (1:1) (9CI)
MF C17 H22 N4 O2 S . C4 H4 O4

CM 1



CM 2

Double bond geometry as shown.



L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Acetic acid, bromo-, 2-(phenylthio)ethyl ester (9CI)
MF C10 H11 Br O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Carbonic acid, 4-[[(4-amino-2-methyl-5-pyrimidinyl)methyl]formylamino]-3-[[[(2-methoxyphenyl)thio]thioxomethyl]thio]-3-pentenyl ethyl ester (9CI)
MF C23 H28 N4 O5 S3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1(2H)-Pyridineethanol, α-[(benzo[b]thien-4-yloxy)methyl]-4-(6-fluoro-2-naphthalenyl)-3,6-dihydro-, (αS)- (9CI)
MF C26 H24 F N O2 S
CI COM

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Acetonitrile, [(3,4-dichlorophenyl)thio]- (9CI)
MF C8 H5 Cl2 N S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN

IN Benzonitrile, 4-(phenylthio)- (9CI)
MF C13 H9 N S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Pyrimidine, 4-(2-butynyloxy)-6-[(2-chlorophenyl)thio]- (9CI)
MF C14 H11 Cl N2 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Sulfonium, diphenyl[4-(phenylthio)phenyl]-, hexafluorophosphate(1-) (9CI)
MF C24 H19 S2 . F6 P

CM 1



CM 2



L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Carbonic acid, 1,2-ethanediyl bis[4-[(1,1-dimethylethyl)azo]-4-[[4-(1,1-dimethylethyl)phenyl]thio]pentyl] ester (9CI)
MF C42 H66 N4 O6 S2

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Pyrazinone, 3-(hexahydro-1H-1,4-diazepin-1-yl)-1-[2-[2-(methylthio)phenoxy]ethyl]- (9CI)
MF C18 H24 N4 O2 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 9,10-Anthracenedione, 1,5-dihydroxy-2,6-bis(2-methylpropyl)-4-(phenylthio)-(9CI)
MF C28 H28 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Acetic acid, (phenylthio)-, ion(2-) (9CI)
MF C8 H6 O2 S



L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Titanium, bis(benzenethiolato)bis(η5-2,4-cyclopentadien-1-yl)- (9CI)
MF C22 H20 S2 Ti
CI CCS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Methanesulfonic acid, trifluoro-, compd. with 1-(methylsulfinyl)-4-(phenylthio)benzene homopolymer (9CI)
MF (C13 H12 O S2)x . x C H F3 O3 S

RELATED POLYMERS AVAILABLE WITH POLYLINK

CM 1



CM 2

CM 3



L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Diazene, (1,1-dimethylethyl)[1-[[4-(1,1-dimethylethyl)phenyl]thio]-3-methoxy-1,3-dimethylbutyl]- (9CI)
MF C21 H36 N2 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Acetyl chloride, (phenylthio)- (6CI, 7CI, 8CI, 9CI)
MF C8 H7 Cl O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Formamide, N,N'-[1,3-propanediylbis[thio[5-(1,1-dimethylethyl)-2,1-

phenylene]]]bis- (9CI)
MF C25 H34 N2 O2 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Diazene, [1,3-dimethyl-1-(phenylthio)butyl](1-methyl-1-phenylethyl)- (9CI)
MF C21 H28 N2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Propanoic acid, 3-[4-(methylthio)phenoxy]- (9CI)
MF C10 H12 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN **2a,5a-(Ethanoxy[3,2]thiopheno[2,3]thiophenoxyethano)-2a,5a-diaza-1,2(2a):1,5(5a)-dihomo[5,6]fullerene-C60-Ih (9CI)**
MF C72 H12 N2 O2 S2
CI RPS

PAGE 1-A



PAGE 2-A



PAGE 3-A



L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Diazene, (1,1-dimethylethyl)[1-(phenylthio)cyclohexyl]- (9CI)
MF C16 H24 N2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN p-Toluenesulfonamide, N-[5,8-diamino-6-chloro-7-(phenylthio)-1-anthraquinonyl]- (8CI)
MF C27 H20 Cl N3 O4 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Cholest-5-en-3-ol (3β)-, S-[4-(phenylthio)phenyl] carbonothioate (9CI)
MF C40 H54 O2 S2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1-Pentanol, 4-[(1,1-dimethylethyl)azo]-4-[[4-(1,1-dimethylethyl)phenyl]thio]-, acetate (ester) (9CI)
MF C21 H34 N2 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Carbonic acid, 4-[[(4-amino-2-methyl-5-pyrimidinyl)methyl]formylamino]-3-[[[(3-methoxyphenyl)thio]thioxomethyl]thio]-3-pentenyl ethyl ester (9CI)
MF C23 H28 N4 O5 S3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1-Piperidineethanol, α-[(benzo[b]thien-4-yloxy)methyl]-4-(3-ethylbenzo[b]thien-2-yl)-, (αS)- (9CI)
MF C26 H29 N O2 S2

09/ 806,836

CI COM

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Acetic acid, chloro-, 2-[(4-chlorophenyl)thio]ethyl ester (9CI)
MF C10 H10 Cl2 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,2-Benzenediamine, 4-(phenylthio)- (9CI)
MF C12 H12 N2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Pyrimidine, 4-(2-butynyloxy)-6-(phenylthio)- (9CI)
MF C14 H12 N2 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Sulfonium, diphenyl[4-(phenylthio)phenyl]-, (OC-6-11)-hexafluoroantimonate(1-) (9CI)
MF C24 H19 S2 . F6 Sb
CI COM

CM 1



CM 2



L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Acetic acid, [(4-chlorophenyl)thio]-, ethyl ester (9CI)
MF C10 H11 Cl O2 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Pyrazinone, 1-[2-[2-(methylthio)phenoxy]ethyl]-3-(1-piperazinyl)-, mono(trifluoroacetate) (9CI)
MF C17 H22 N4 O2 S . C2 H F3 O2

CM 1



CM 2



L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Sulfonium, dimethyl[4-(phenylthio)phenyl]-, (OC-6-11)-hexafluoroantimonate(1-) (9CI)
MF C14 H15 S2 . F6 Sb

CM 1



CM 2



L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,3-Benzodioxole, 5-[[5-(3,3-dimethyloxiranyl)-3-methyl-2-pentenyl]thio]-(9CI)
MF C17 H22 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzenethiol, copper(1+) salt (8CI, 9CI)
MF C6 H6 S . Cu
CI COM



● Cu(I)

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Sulfonium, (4-mercaptophenoxy)diphenyl-, (OC-6-11)-hexafluoroantimonate(1-) (9CI)
MF C18 H15 O S2 . F6 Sb

CM 1



CM 2



L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Diazene, (1,1-dimethylethyl)[1-[[4-(1,1-dimethylethyl)phenyl]thio]-1,3-dimethylbutyl]- (9CI)
MF C20 H34 N2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Methanone, phenyl[4-(phenylthio)phenyl]- (9CI)
MF C19 H14 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzenamine, 2,2'-[2,6-pyridinediylbis(methylenethio)]bis- (9CI)
MF C19 H19 N3 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Diazene, (1,1-dimethylethyl)[1-[[4-(1,1-dimethylethyl)phenyl]thio]-1-phenylethyl]- (9CI)
MF C22 H30 N2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzene, 1,1'-[methylenebis(thio)]bis[4-nitro- (9CI)
MF C13 H10 N2 O4 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1-Propanone, 1-(3,4-dimethoxyphenyl)-2-(phenylthio)- (9CI)
MF C17 H18 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Diazene, (1,1-dimethylethyl)[2,2,4-trimethyl-1-(phenylthio)cyclopentyl]-
(9CI)
MF C18 H28 N2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2-Propanol, 1-[(1-methylethyl)amino]-3-[2-(methylthio)phenoxy]- (9CI)
MF C13 H21 N O2 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Cholest-5-en-3-ol (3β)-, [4-(phenylthio)phenyl]carbamate (9CI)
MF C40 H55 N O2 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1-Pentanol, 4-[(1,1-dimethylethyl)azo]-4-[[4-(1,1-dimethylethyl)phenyl]thio]- (9CI)
MF C19 H32 N2 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Phenol, 4,4'-[(diethylsilylene)bis(thio)]bis[2,6-bis(1,1-dimethylethyl)-(9CI)
MF C32 H52 O2 S2 Si



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1-Piperidineethanol, α-[(benzo[b]thien-4-yloxy)methyl]-4-(3-methylbenzo[b]thien-2-yl)-, (αS)- (9CI)
MF C25 H27 N O2 S2
CI COM

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Acetic acid, bromo-, 2-[(4-chlorophenyl)thio]ethyl ester (9CI)
MF C10 H10 Br Cl O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Phenol, 4-[4-(methylthio)phenoxy]- (9CI)
MF C13 H12 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1H-Thieno[3,4-g]indazole-6-carboxylic acid, 4,5-dihydro-1-methyl-8-[4-(methylthio)phenoxy]-, ethyl ester (9CI)
MF C20 H20 N2 O3 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Cyclohexanol, 2-[4-(phenylthio)phenoxy]- (9CI)
MF C18 H20 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,2-Benzenedicarbonitrile, 3-(phenylthio)- (9CI)
MF C14 H8 N2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Pyrazinone, 1-[2-[2-(methylthio)phenoxy]ethyl]-3-(1-piperazinyl)-(9CI)
MF C17 H22 N4 O2 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzonitrile, 4-[(4-chlorophenyl)thio]- (9CI)
MF C13 H8 Cl N S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzene, 1-(2,2-diethoxyethoxy)-4-(methylthio)- (9CI)
MF C13 H20 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L1 91 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Phenothiatellurin (8CI, 9CI)
MF C12 H8 S Te
CI RPS



ALL ANSWERS HAVE BEEN SCANNED

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	6.32	6.53

FILE 'CAPLUS' ENTERED AT 14:10:22 ON 04 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 4 Feb 2005 VOL 142 ISS 6
FILE LAST UPDATED: 2 Feb 2005 (20050202/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s angiogenesis and atherosclerosis
25316 ANGIOGENESIS
42586 ATHEROSCLEROSIS

09/ 806,836

L2 1088 ANGIOGENESIS AND ATHEROSCLEROSIS

=> s l2 not py>1998
5939426 PY>1998
L3 106 L2 NOT PY>1998

=> s l3 and quinazolin?
12435 QUINAZOLIN?
L4 0 L3 AND QUINAZOLIN?

=> d l3 1-10

L3 ANSWER 1 OF 106 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:604313 CAPLUS
DN 132:136037
TI Chemokines
AU Iizawa, Hisashi; Matsushima, Kouji
CS Department of Pharmacy, Kyoritsu Pharmaceutical University, Japan
SO Saitokain no Kino o Saguru (1998), 99-105. Editor(s): Miyajima, Atsushi. Publisher: Yodosha, Tokyo, Japan.
CODEN: 68DRAS
DT Conference; General Review
LA Japanese

L3 ANSWER 2 OF 106 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:393479 CAPLUS
DN 131:209213
TI Heparin-binding epidermal growth factor-like growth factor (HB-EGF)
AU Fukuda, Kazuto; Igura, Takumi; Kawata, Sumio; Matsuzawa, Yuji
CS Faculty of Medicine, Osaka University, Japan
SO Kekkan Rimoderingu to Shushoku Inshi (1997), 159-166. Editor(s): Yazaki, Yoshio. Publisher: Medikaru Rebyusha, Tokyo, Japan.
CODEN: 67UGA5
DT Conference; General Review
LA Japanese

L3 ANSWER 3 OF 106 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:43702 CAPLUS
DN 130:104668
TI Natural products as **angiogenesis** inhibitors
AU Paper, Dietrich H.
CS Department Pharmacy, University Regensburg, Regensburg, D-93040, Germany
SO Planta Medica (1998), 64(8), 686-695
CODEN: PLMEAA; ISSN: 0032-0943
PB Georg Thieme Verlag
DT Journal; General Review
LA English
RE.CNT 124 THERE ARE 124 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 106 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:797398 CAPLUS
DN 130:108545
TI Mapping of vascular dendritic cells in atherosclerotic arteries suggests their involvement in local immune-inflammatory reactions. [Erratum to document cited in CA129:66293]
AU Bobryshev, Yuri V.; Lord, Reginald S. A.
CS St. Vincent's Hospital, Surgical Professorial Unit, University of New South Wales, Sydney, Australia
SO Cardiovascular Research (1998), 40(3), 607
CODEN: CVREAU; ISSN: 0008-6363

PB Elsevier Science B.V.
DT Journal
LA English

L3 ANSWER 5 OF 106 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:792902 CAPLUS
DN 130:180895
TI Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: Possible pathophysiological significance of VEGF in progression of **atherosclerosis**
AU Inoue, Mayumi; Itoh, Hiroshi; Ueda, Makiko; Naruko, Takahiko; Kojima, Akiko; Komatsu, Ryushi; Doi, Kentaro; Ogawa, Yoshihiro; Tamura, Naohisa; Takaya, Kazuhiko; Igaki, Toshio; Yamashita, Jun; Chun, Tae-Hwa; Masatsugu, Ken; Becker, Anton E.; Nakao, Kazuwa
CS Department of Medicine and Clinical Science, Kyoto University Graduate School of Medicine, Kyoto, 606-8507, Japan
SO Circulation (1998), 98(20), 2108-2116
CODEN: CIRCAZ; ISSN: 0009-7322
PB Lippincott Williams & Wilkins
DT Journal
LA English
RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 106 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:750811 CAPLUS
DN 130:123458
TI Molecular interactions between the urokinase receptor and integrins in the vasculature
AU May, A. E.; Kanse, S. M.; Chavakis, T.; Preissner, K. T.
CS Haemostasis Research Unit, Kerckhoff-Klinik, Max-Planck-Institut, Bad Nauheim, D-61231, Germany
SO Fibrinolysis & Proteolysis (1998), 12(4), 205-210
CODEN: FBPRFP; ISSN: 1369-0191
PB Churchill Livingstone
DT Journal; General Review
LA English
RE.CNT 65 THERE ARE 65 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 106 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:727038 CAPLUS
DN 130:89962
TI Vascular gene transfer for the treatment of restenosis and **atherosclerosis**
AU Laitinen, Marja; Yla-Herttuala, Seppo
CS A.I. Virtanen Institute and Department of Medicine, Gene Therapy Unit, Kuopio University Central Hospital, University of Kuopio, Kuopio, FIN-70211, Finland
SO Current Opinion in Lipidology (1998), 9(5), 465-469
CODEN: COPLEU; ISSN: 0957-9672
PB Lippincott-Raven Publishers
DT Journal; General Review
LA English
RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 106 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:727032 CAPLUS
DN 130:93530
TI Tissue inhibitors of metalloproteinases and metalloproteinases in

atherosclerosis
AU George, Sarah Jane
CS Bristol Heart Institute, Bristol, BS2 8HW, UK
SO Current Opinion in Lipidology (1998), 9(5), 413-423
CODEN: COPLEU; ISSN: 0957-9672
PB Lippincott-Raven Publishers
DT Journal; General Review
LA English
RE.CNT 134 THERE ARE 134 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 106 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:726788 CAPLUS
DN 130:90593
TI Vascular endothelial growth factor-C: a growth factor for lymphatic and blood vascular endothelial cells
AU Enholm, Berndt; Jussila, Lotta; Karkkainen, Marika; Alitalo, Kari
CS Molecular/Cancer Biology Laboratory, Haartman Institute, University of Helsinki, Helsinki, 00014, Finland
SO Trends in Cardiovascular Medicine (1998), 8(7), 292-297
CODEN: TCMDEQ; ISSN: 1050-1738
PB Elsevier Science Inc.
DT Journal; General Review
LA English
RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 10 OF 106 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:724585 CAPLUS
DN 130:90084
TI Crystal structure of an **angiogenesis** inhibitor bound to the FGF receptor tyrosine kinase domain
AU Mohammadi, Moosa; Froum, Scott; Hamby, James M.; Schroeder, Mel C.; Panek, Robert L.; Lu, Gina H.; Eliseenkova, Anna V.; Green, David; Schlessinger, Joseph; Hubbard, Stevan R.
CS Departments of Pharmacology and Medicine, Kaplan Comprehensive Cancer Center, and Skirball Institute of Biomolecular Medicine, New York University Medical Center, New York, NY, 10016, USA
SO EMBO Journal (1998), 17(20), 5896-5904
CODEN: EMJODG; ISSN: 0261-4189
PB Oxford University Press
DT Journal
LA English
RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l3 1-10 ibib abs

L3 ANSWER 1 OF 106 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:604313 CAPLUS
DOCUMENT NUMBER: 132:136037
TITLE: Chemokines
AUTHOR(S): Iizawa, Hisashi; Matsushima, Kouji
CORPORATE SOURCE: Department of Pharmacy, Kyoritsu Pharmaceutical University, Japan
SOURCE: Saitokain no Kino o Saguru (1998), 99-105. Editor(s): Miyajima, Atsushi. Yodosha: Tokyo, Japan.
CODEN: 68DRAS
DOCUMENT TYPE: Conference; General Review
LANGUAGE: Japanese

AB A review with 10 refs., on chemokine family, receptor specificity, and role chemokines in cytokine formation, lymphocyte homing, brain development and **angiogenesis**, HIV infection, Th1/Th2, and **atherosclerosis**.

L3 ANSWER 2 OF 106 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:393479 CAPLUS
DOCUMENT NUMBER: 131:209213
TITLE: Heparin-binding epidermal growth factor-like growth factor (HB-EGF)
AUTHOR(S): Fukuda, Kazuto; Igura, Takumi; Kawata, Sumio; Matsuzawa, Yuji
CORPORATE SOURCE: Faculty of Medicine, Osaka University, Japan
SOURCE: Kekkan Rimoderingu to Shushoku Inshi (1997), 159-166. Editor(s): Yazaki, Yoshio. Medikaru Rebyusha: Tokyo, Japan.
CODEN: 67UGA5
DOCUMENT TYPE: Conference; General Review
LANGUAGE: Japanese
AB A review with 16 refs., on role of HB-EGF in vascular remodeling, discussing HB-EGF structure and signal transduction; HB-EGF expression in **atherosclerosis**; HB-EGF in regulation of vascular smooth muscle cell migration and proliferation; and role of HB-EGF in vascular remodeling.

L3 ANSWER 3 OF 106 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:43702 CAPLUS
DOCUMENT NUMBER: 130:104668
TITLE: Natural products as **angiogenesis** inhibitors
AUTHOR(S): Paper, Dietrich H.
CORPORATE SOURCE: Department Pharmacy, University Regensburg, Regensburg, D-93040, Germany
SOURCE: Planta Medica (1998), 64(8), 686-695
CODEN: PLMEAA; ISSN: 0032-0943
PUBLISHER: Georg Thieme Verlag
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB **Angiogenesis** is a strictly controlled process in the healthy, adult human body. It is regulated by a variety of endogenous angiogenic and angiostatic factors. It is only switched on, e.g., during wound healing. Pathol. **angiogenesis** occurs, for example, in cancer, chronic inflammation, or **atherosclerosis**. **Angiogenesis** inhibitors are able to interfere with various steps of **angiogenesis**, like basement destruction of blood vessels, proliferation and migration of endothelial cells, or the lumen formation. Among the known **angiogenesis** inhibitors compds. derived from natural sources, like flavonoids, sulfated carbohydrates, or triterpenoids are playing a prominent role. This article is reviewed by 124 refs.
REFERENCE COUNT: 124 THERE ARE 124 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 106 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:797398 CAPLUS
DOCUMENT NUMBER: 130:108545
TITLE: Mapping of vascular dendritic cells in atherosclerotic arteries suggests their involvement in local immune-inflammatory reactions. [Erratum to document cited in CA129:66293]
AUTHOR(S): Bobryshev, Yuri V.; Lord, Reginald S. A.
CORPORATE SOURCE: St. Vincent's Hospital, Surgical Professorial Unit,

University of New South Wales, Sydney, Australia
SOURCE: Cardiovascular Research (1998), 40(3), 607
CODEN: CVREAU; ISSN: 0008-6363
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The corrected Table 2 is given.

L3 ANSWER 5 OF 106 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:792902 CAPLUS
DOCUMENT NUMBER: 130:180895
TITLE: Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: Possible pathophysiological significance of VEGF in progression of **atherosclerosis**
AUTHOR(S): Inoue, Mayumi; Itoh, Hiroshi; Ueda, Makiko; Naruko, Takahiko; Kojima, Akiko; Komatsu, Ryushi; Doi, Kentaro; Ogawa, Yoshihiro; Tamura, Naohisa; Takaya, Kazuhiko; Igaki, Toshio; Yamashita, Jun; Chun, Tae-Hwa; Masatsugu, Ken; Becker, Anton E.; Nakao, Kazuwa
CORPORATE SOURCE: Department of Medicine and Clinical Science, Kyoto University Graduate School of Medicine, Kyoto, 606-8507, Japan
SOURCE: Circulation (1998), 98(20), 2108-2116
CODEN: CIRCAZ; ISSN: 0009-7322
PUBLISHER: Lippincott Williams & Wilkins
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Vascular endothelial growth factor (VEGF) is an important angiogenic factor reported to induce migration and proliferation of endothelial cells, enhance vascular permeability, and modulate thrombogenicity. VEGF expression in cultured cells (smooth muscle cells, macrophages, endothelial cells) is controlled by growth factors and cytokines. Hence, the question arises of whether VEGF could play a role in atherogenesis. Frozen sections from 38 coronary artery segments were studied. The specimens were characterized as normal with diffuse intimal thickening, early **atherosclerosis** with hypercellularity, and advanced **atherosclerosis** (atheromatous plaques, fibrous plaques, and totally occlusive lesions). VEGF expression as well as the expression of 2 VEGF receptors, flt-1 and Flk-1, were studied with immunohistochem. techniques in these samples at the different stages of human coronary **atherosclerosis** progression. The expression of VEGF mRNA was also studied with reverse transcription-polymerase chain reaction. Normal arterial segments showed no substantial VEGF expression. Hypercellular and atheromatous lesions showed distinct VEGF positivity of activated endothelial cells, macrophages, and partially differentiated smooth muscle cells. VEGF positivity was also detected in endothelial cells of intraplaque microvessels within advanced lesions. In totally occlusive lesions with extensive neovascularization, intense immunostaining for VEGF was observed in accumulated macrophages and endothelial cells of the microvessels. Furthermore, VEGF mRNA expression was detected in atherosclerotic coronary segments but not in normal coronary segments. The immunostainings for flt-1 and Flk-1 were detected in aggregating macrophages in atherosclerotic lesions and also in endothelial cells of the microvessels in totally occlusive lesions. These results demonstrate distinct expression of VEGF and its receptors (flt-1 and Flk-1) in atherosclerotic lesions in human coronary arteries. Considering the multipotent actions of VEGF documented exptl. in vivo and in vitro, the findings suggest that VEGF may have some role in the progression of human coronary **atherosclerosis**, as well as in recanalization processes

in obstructive coronary diseases.
REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 106 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:750811 CAPLUS
DOCUMENT NUMBER: 130:123458
TITLE: Molecular interactions between the urokinase receptor and integrins in the vasculature
AUTHOR(S): May, A. E.; Kanse, S. M.; Chavakis, T.; Preissner, K. T.
CORPORATE SOURCE: Haemostasis Research Unit, Kerckhoff-Klinik, Max-Planck-Institut, Bad Nauheim, D-61231, Germany
SOURCE: Fibrinolysis & Proteolysis (1998), 12(4), 205-210
CODEN: FBPRFP; ISSN: 1369-0191
PUBLISHER: Churchill Livingstone
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review with 65 refs. Cell-cell and cell-extracellular matrix (ECM) interactions are key events in morphogenic processes during developmental and reproductive phases, in immune defense, wound healing and tissue repair, or hemostasis. Their dysregulation plays a major role in the pathophysiol. of cardiovascular diseases (**atherosclerosis**, restenosis, thrombosis) or **angiogenesis**-driven tumor progression. Protease cascades such as the plasminogen activation system are linked to cell adhesion and migration. The urokinase-type plasminogen activator (uPA) as well as its receptor (uPAR) has been found in a complex with β1-, β2-, and β3-integrins, thereby allowing mutual interactions and regulatory processes between cell adhesion and proteolysis to occur. Moreover, both uPAR and PAI-1 are capable of binding to vitronectin, an adhesive ECM protein, that serves as ligand for vascular integrins in an RGD-dependent manner. Here, the authors focus on the mol. and functional interactions between the uPAR system and vascular integrins and discuss consequences for vascular cell functions.
REFERENCE COUNT: 65 THERE ARE 65 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 106 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:727038 CAPLUS
DOCUMENT NUMBER: 130:89962
TITLE: Vascular gene transfer for the treatment of restenosis and **atherosclerosis**
AUTHOR(S): Laitinen, Marja; Yla-Herttuala, Seppo
CORPORATE SOURCE: A.I. Virtanen Institute and Department of Medicine, Gene Therapy Unit, Kuopio University Central Hospital, University of Kuopio, Kuopio, FIN-70211, Finland
SOURCE: Current Opinion in Lipidology (1998), 9(5), 465-469
CODEN: COPLEU; ISSN: 0957-9672
PUBLISHER: Lippincott-Raven Publishers
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review with 61 refs. Local gene transfer into the vascular wall offers a promising alternative to treat **atherosclerosis**-related diseases at cellular and mol. levels. Blood vessels are among the easiest targets for gene therapy because of novel percutaneous, catheter-based treatment methods. On the other hand, gene transfer to the artery wall can also be accomplished from adventitia, and in some situations i.m. gene delivery is also a possibility. In most conditions, such as postangioplasty restenosis, only a temporary expression of the transfected gene will be required. Promising therapeutic effects have been obtained in animal models of restenosis with the transfer of genes for vascular

endothelial growth factor, fibroblast growth factor, thymidine kinase, p53, bcl-x, nitric oxide synthase and retinoblastoma. Also, growth arrest homeobox gene and antisense oligonucleotides against transcription factors or cell cycle regulatory proteins have produced beneficial therapeutic effects. **Angiogenesis** is an emerging new target for gene therapy of ischemic diseases. In addition, hyperlipoproteinemias may be improved by transferring functional lipoprotein-receptor genes into hepatocytes of affected individuals. First experiences of gene transfer methods in the human vascular system have been reported. However, further studies regarding gene delivery methods, vectors and safety of the procedures are needed before a full therapeutic potential of gene therapy in vascular diseases can be evaluated.

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 106 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:727032 CAPLUS
DOCUMENT NUMBER: 130:93530
TITLE: Tissue inhibitors of metalloproteinases and metalloproteinases in **atherosclerosis**
AUTHOR(S): George, Sarah Jane
CORPORATE SOURCE: Bristol Heart Institute, Bristol, BS2 8HW, UK
SOURCE: Current Opinion in Lipidology (1998), 9(5), 413-423
CODEN: COPLEU; ISSN: 0957-9672
PUBLISHER: Lippincott-Raven Publishers
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review, with 134 refs. The ability of the metalloproteinases to degrade extracellular matrix proteins is essential for the matrix remodelling that occurs during infiltration of inflammatory cells, intimal thickening, **angiogenesis** and plaque rupture which are a result of **atherosclerosis**. Increased metalloproteinase activity therefore requires stimulation of metalloproteinase expression by cytokines and growth factors, activation of metalloproteinases, and downregulation of tissue inhibitors of metalloproteinases. In addition, metalloproteinases may influence **atherosclerosis** by processing of proteins involved in inflammation and cell growth and death and the tissue inhibitors of metalloproteinases may also play a less inhibitory role by influencing cell growth and apoptosis.
REFERENCE COUNT: 134 THERE ARE 134 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 106 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:726788 CAPLUS
DOCUMENT NUMBER: 130:90593
TITLE: Vascular endothelial growth factor-C: a growth factor for lymphatic and blood vascular endothelial cells
AUTHOR(S): Enholm, Berndt; Jussila, Lotta; Karkkainen, Marika; Alitalo, Kari
CORPORATE SOURCE: Molecular/Cancer Biology Laboratory, Haartman Institute, University of Helsinki, Helsinki, 00014, Finland
SOURCE: Trends in Cardiovascular Medicine (1998), 8(7), 292-297
CODEN: TCMDEQ; ISSN: 1050-1738
PUBLISHER: Elsevier Science Inc.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review with .apprx.30 refs. The endothelial cells lining all vessels of the circulatory system have been recognized as key players in a variety of

physiol. and pathol. settings. They act as regulators of vascular tone via the inducible nitric oxide system and in **angiogenesis**, the formation of blood vessels de novo. Aberrant regulation of endothelial cells contributes to tumor formation, **atherosclerosis**, and diseases such as psoriasis and rheumatoid arthritis. Among the most recently discovered growth factors for endothelial cells are newly isolated members of the platelet-derived growth factor/vascular endothelial growth factor (VEGF) family, VEGF-B, VEGF-C, and VEGF-D. VEGF-C is the ligand for the receptor tyrosine kinase VEGFR-3 (also known as Flt4), which is expressed predominantly in lymphatic endothelium of adult tissues, but a proteolytically processed form of VEGF-C can also activate VEGFR-2 of blood vessels. The lymphatic vessels have been known since the 17th century, but their specific roles in health and disease are still poorly understood. With the discovery of VEGF-C and its cognate receptor VEGFR-3, the regulation and functions of this important component of the circulatory system can be investigated.

REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 10 OF 106 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:724585 CAPLUS
DOCUMENT NUMBER: 130:90084
TITLE: Crystal structure of an **angiogenesis** inhibitor bound to the FGF receptor tyrosine kinase domain
AUTHOR(S): Mohammadi, Moosa; Froum, Scott; Hamby, James M.; Schroeder, Mel C.; Panek, Robert L.; Lu, Gina H.; Eliseenkova, Anna V.; Green, David; Schlessinger, Joseph; Hubbard, Stevan R.
CORPORATE SOURCE: Departments of Pharmacology and Medicine, Kaplan Comprehensive Cancer Center, and Skirball Institute of Biomolecular Medicine, New York University Medical Center, New York, NY, 10016, USA
SOURCE: EMBO Journal (1998), 17(20), 5896-5904
CODEN: EMJODG; ISSN: 0261-4189
PUBLISHER: Oxford University Press
DOCUMENT TYPE: Journal
LANGUAGE: English

AB **Angiogenesis**, the sprouting of new blood vessels from pre-existing ones, is an essential physiol. process in development, yet also plays a major role in the progression of human diseases such as diabetic retinopathy, **atherosclerosis** and cancer. The effects of the most potent angiogenic factors, vascular endothelial growth factor (VEGF), angiopoietin and fibroblast growth factor (FGF) are mediated through cell surface receptors that possess intrinsic protein tyrosine kinase activity. In this report, the authors describe a synthetic compound of the pyrido[2,3-d]pyrimidine class, designated PD 173074, that selectively inhibits the tyrosine kinase activities of the FGF and VEGF receptors. The authors show that systemic administration of PD 173074 in mice can effectively block **angiogenesis** induced by either FGF or VEGF with no apparent toxicity. To elucidate the determinants of selectivity, the authors have determined the crystal structure of PD 173074 in complex with the tyrosine kinase domain of FGF receptor 1 at 2.5 Å resolution A high degree of surface complementarity between PD 173074 and the hydrophobic, ATP-binding pocket of FGF receptor 1 underlies the potency and selectivity of this inhibitor. PD 173074 is thus a promising candidate for a therapeutic **angiogenesis** inhibitor to be used in the treatment of cancer and other diseases whose progression is dependent upon new blood vessel formation.

REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT